Australian Broker Call
Produced and copyrighted by at www.fnarena.com
September 19, 2018
Access Broker Call Report Archives here
COMPANIES DISCUSSED IN THIS ISSUE
Click on symbol for fast access.
The number next to the symbol represents the number of brokers covering it for this report -(if more than 1)
Last Updated: 02:40 PM
Your daily news report on the latest recommendation, valuation, forecast and opinion changes.
This report includes concise but limited reviews of research recently published by Stockbrokers, which should be considered as information concerning likely market behaviour rather than advice on the securities mentioned. Do not act on the contents of this Report without first reading the important information included at the end.
For more info about the different terms used by stockbrokers, as well as the different methodologies behind similar sounding ratings, download our guide HERE
Today's Upgrades and Downgrades
CGC - | COSTA GROUP | Upgrade to Buy from Neutral | UBS |
EHE - | ESTIA HEALTH | Downgrade to Neutral from Outperform | Macquarie |
JHC - | JAPARA HEALTHCARE | Downgrade to Underperform from Neutral | Macquarie |
Overnight Price: $1.58
Morgans rates AFG as Add (1) -
Australian Finance Group has followed the big banks in lifting its variable mortgage rate by 15 basis points. The broker has lifted its earnings forecast by 0.55% to reflect a higher net interest margin assumption.
Add and $2.00 target retained.
Target price is $2.00 Current Price is $1.58 Difference: $0.42
If AFG meets the Morgans target it will return approximately 27% (excluding dividends, fees and charges).
The company's fiscal year ends in June.
Forecast for FY19:
Morgans forecasts a full year FY19 dividend of 11.00 cents and EPS of 16.00 cents. |
Forecast for FY20:
Morgans forecasts a full year FY20 dividend of 14.00 cents and EPS of 18.00 cents. |
Market Sentiment: 1.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
BRG BREVILLE GROUP LIMITED
Household & Personal Products
More Research Tools In Stock Analysis - click HERE
Overnight Price: $13.07
Ord Minnett rates BRG as Buy (1) -
Ord Minnett considers the latest developments regarding the US/China tariff wars are negative for sentiment as a number of goods in the Breville product line are included on the list. However, even in a worst-case scenario, retail prices would have to increase by just 10% to counter the effect of the tariffs. This is made more achievable by the relatively unique, high-in nature of Breville's products.
The broker maintains a Buy rating and $15.16 target. Ord Minnett notes the majority of manufacturing costs are born in US dollars and would expect the margins of the Australasian business to decrease as the Australian dollar weakens. The company is partially hedged against a weaker Australian dollar.
This stock is not covered in-house by Ord Minnett. Instead, the broker whitelabels research by JP Morgan.
Target price is $15.16 Current Price is $13.07 Difference: $2.09
If BRG meets the Ord Minnett target it will return approximately 16% (excluding dividends, fees and charges).
Current consensus price target is $13.81, suggesting upside of 5.7% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY19:
Ord Minnett forecasts a full year FY19 dividend of 39.00 cents and EPS of 53.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 52.2, implying annual growth of 16.0%. Current consensus DPS estimate is 37.8, implying a prospective dividend yield of 2.9%. Current consensus EPS estimate suggests the PER is 25.0. |
Forecast for FY20:
Ord Minnett forecasts a full year FY20 dividend of 42.00 cents and EPS of 58.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 57.5, implying annual growth of 10.2%. Current consensus DPS estimate is 42.3, implying a prospective dividend yield of 3.2%. Current consensus EPS estimate suggests the PER is 22.7. |
Market Sentiment: 0.3
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Overnight Price: $6.81
UBS rates CGC as Upgrade to Buy from Neutral (1) -
The share price has underperformed since the August results and UBS upgrades to Buy from Neutral. Supporting the upgrade is the stronger wholesale produce pricing and the growth projects.
Upside is expected to FY19 guidance for low double-digit net profit growth, albeit limited, and the broker suggests there is a risk of a large skew to the second half.
Still, the outlook is considered priced in as expectations have been re-based post the FY18 result. Target is steady at $8.20.
Target price is $8.20 Current Price is $6.81 Difference: $1.39
If CGC meets the UBS target it will return approximately 20% (excluding dividends, fees and charges).
Current consensus price target is $7.70, suggesting upside of 13.1% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY19:
UBS forecasts a full year FY19 dividend of 15.00 cents and EPS of 27.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 27.6, implying annual growth of -18.4%. Current consensus DPS estimate is 15.3, implying a prospective dividend yield of 2.2%. Current consensus EPS estimate suggests the PER is 24.7. |
Forecast for FY20:
UBS forecasts a full year FY20 dividend of 18.00 cents and EPS of 32.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 31.1, implying annual growth of 12.7%. Current consensus DPS estimate is 17.1, implying a prospective dividend yield of 2.5%. Current consensus EPS estimate suggests the PER is 21.9. |
Market Sentiment: 0.3
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
CGF CHALLENGER LIMITED
Wealth Management & Investments
More Research Tools In Stock Analysis - click HERE
Overnight Price: $10.94
Credit Suisse rates CGF as Neutral (3) -
Credit Suisse observes the company has been criticised recently for its approach to operating earnings. The broker notes the approach to disclosures is similar to many of Challenger's insurance peers.
The purpose of normalised assumptions is to better represent underlying earnings by stripping out volatility because of markets. Over a longer timeframe, which incorporates the GFC, the company's investment experience has been negative. However, Credit Suisse asserts this is no different to the volatility experienced by other risk-bearing regulated financial services.
The broker maintains a Neutral rating and $12 target.
Target price is $12.00 Current Price is $10.94 Difference: $1.06
If CGF meets the Credit Suisse target it will return approximately 10% (excluding dividends, fees and charges).
Current consensus price target is $11.64, suggesting upside of 6.4% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY19:
Credit Suisse forecasts a full year FY19 dividend of 37.00 cents and EPS of 66.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 63.7, implying annual growth of 18.0%. Current consensus DPS estimate is 36.2, implying a prospective dividend yield of 3.3%. Current consensus EPS estimate suggests the PER is 17.2. |
Forecast for FY20:
Credit Suisse forecasts a full year FY20 dividend of 38.00 cents and EPS of 74.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 68.9, implying annual growth of 8.2%. Current consensus DPS estimate is 37.6, implying a prospective dividend yield of 3.4%. Current consensus EPS estimate suggests the PER is 15.9. |
Market Sentiment: 0.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Overnight Price: $29.79
Morgan Stanley rates CTX as Underweight (5) -
Morgan Stanley suggests the risk/reward at Caltex is better now, given the recent share price performance. The new reporting indicates two businesses on different trajectories. The broker finds clear signs of higher oil prices, consumer pressure and greater competition when analysing the retail fuel trends.
The broker suggests the bull argument around infrastructure appears less likely and the challenge will be pricing the fresh food/convenience strategy, given the uncertainty.
Underweight and $26 target retained. Industry view: Attractive.
Target price is $26.00 Current Price is $29.79 Difference: minus $3.79 (current price is over target).
If CTX meets the Morgan Stanley target it will return approximately minus 13% (excluding dividends, fees and charges - negative figures indicate an expected loss).
Current consensus price target is $34.29, suggesting upside of 15.1% (ex-dividends)
The company's fiscal year ends in December.
Forecast for FY18:
Morgan Stanley forecasts a full year FY18 dividend of 109.00 cents and EPS of 217.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 227.5, implying annual growth of -4.4%. Current consensus DPS estimate is 111.8, implying a prospective dividend yield of 3.8%. Current consensus EPS estimate suggests the PER is 13.1. |
Forecast for FY19:
Morgan Stanley forecasts a full year FY19 dividend of 104.00 cents and EPS of 207.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 231.3, implying annual growth of 1.7%. Current consensus DPS estimate is 117.6, implying a prospective dividend yield of 3.9%. Current consensus EPS estimate suggests the PER is 12.9. |
Market Sentiment: 0.4
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Overnight Price: $2.37
Macquarie rates EHE as Downgrade to Neutral from Outperform (3) -
The Australian government has announced a royal commission into the aged care industry. Macquarie suggests negative media coverage and scrutiny from a royal commission will increase the likelihood of falling occupancy.
Despite having a cautious view on the aged care sector, the company's balance sheet and consistent conservative growth made Estia Health the broker's preference among listed operators.
However, given the negative coverage Macquarie considers the stock unlikely to outperform and the rating is downgraded to Neutral. Target is reduced to $2.70 from $3.60.
Target price is $2.70 Current Price is $2.37 Difference: $0.33
If EHE meets the Macquarie target it will return approximately 14% (excluding dividends, fees and charges).
Current consensus price target is $3.29, suggesting upside of 38.7% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY19:
Macquarie forecasts a full year FY19 dividend of 17.90 cents and EPS of 17.50 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 17.6, implying annual growth of 11.4%. Current consensus DPS estimate is 16.4, implying a prospective dividend yield of 6.9%. Current consensus EPS estimate suggests the PER is 13.5. |
Forecast for FY20:
Macquarie forecasts a full year FY20 dividend of 18.00 cents and EPS of 18.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 19.0, implying annual growth of 8.0%. Current consensus DPS estimate is 17.5, implying a prospective dividend yield of 7.4%. Current consensus EPS estimate suggests the PER is 12.5. |
Market Sentiment: 0.3
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
JHC JAPARA HEALTHCARE LIMITED
Aged Care & Seniors
More Research Tools In Stock Analysis - click HERE
Overnight Price: $1.35
Macquarie rates JHC as Downgrade to Underperform from Neutral (5) -
The Australian government has announced a royal commission into the aged care industry. Given the increased scrutiny and attention operators will receive in FY19, Macquarie believes there is increased risk from the company's strategy of reducing staff costs.
Consistent with the broker's view of the industry, there is a risk of falling occupancy throughout FY19. The earnings impact from a change in occupancy is greater for Japara Healthcare than its listed peers and the broker downgrades to Underperform from Neutral. Target is reduced to $1.33 from $1.77.
Target price is $1.33 Current Price is $1.35 Difference: minus $0.02 (current price is over target).
If JHC meets the Macquarie target it will return approximately minus 1% (excluding dividends, fees and charges - negative figures indicate an expected loss).
Current consensus price target is $1.61, suggesting upside of 19.6% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY19:
Macquarie forecasts a full year FY19 dividend of 7.40 cents and EPS of 7.40 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 7.9, implying annual growth of -10.0%. Current consensus DPS estimate is 7.6, implying a prospective dividend yield of 5.6%. Current consensus EPS estimate suggests the PER is 17.1. |
Forecast for FY20:
Macquarie forecasts a full year FY20 dividend of 8.70 cents and EPS of 8.70 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 9.2, implying annual growth of 16.5%. Current consensus DPS estimate is 8.7, implying a prospective dividend yield of 6.4%. Current consensus EPS estimate suggests the PER is 14.7. |
Market Sentiment: -0.6
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
KMD KATHMANDU HOLDINGS LIMITED
Sports & Recreation
More Research Tools In Stock Analysis - click HERE
Overnight Price: $2.88
Credit Suisse rates KMD as Neutral (3) -
FY18 net profit was in line with guidance and above Credit Suisse forecasts. The broker considers this a strong result that reflects robust same-store sales growth in Australia and better gross margins. There was less discounting and higher average selling prices.
The company did not provide specific guidance for FY19, although noted the expected impact of higher input costs and FX pressures in the second half.
Credit Suisse acknowledges the actions taken to reduce operating risk but, despite recent margin improvement, struggles to envisage sufficient upside to support a more positive view. Neutral rating maintained. Target rises to NZ$3.25 from NZ$3.10.
Current Price is $2.88. Target price not assessed.
Current consensus price target is $3.07, suggesting upside of 6.4% (ex-dividends)
The company's fiscal year ends in July.
Forecast for FY19:
Credit Suisse forecasts a full year FY19 dividend of 14.70 cents and EPS of 24.44 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 23.1, implying annual growth of N/A. Current consensus DPS estimate is 14.4, implying a prospective dividend yield of 5.0%. Current consensus EPS estimate suggests the PER is 12.5. |
Forecast for FY20:
Credit Suisse forecasts a full year FY20 dividend of 16.54 cents and EPS of 25.91 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 24.5, implying annual growth of 6.1%. Current consensus DPS estimate is 15.8, implying a prospective dividend yield of 5.5%. Current consensus EPS estimate suggests the PER is 11.8. |
This company reports in NZD. All estimates have been converted into AUD by FNArena at present FX values.
Market Sentiment: 0.5
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Macquarie rates KMD as Outperform (1) -
Macquarie believes Kathmandu is executing well against its strategy. Sales growth in FY18 was supported by the Oboz acquisition and new stores. Group sales rose 11.7%, or 6.1% excluding the Oboz acquisition.
Gross margin improved 1.4% to 63.4%, supported by less discounting and higher selling prices. Macquarie maintains an Outperform rating. Target is raised to $3.13 from $2.98.
Target price is $3.13 Current Price is $2.88 Difference: $0.25
If KMD meets the Macquarie target it will return approximately 9% (excluding dividends, fees and charges).
Current consensus price target is $3.07, suggesting upside of 6.4% (ex-dividends)
The company's fiscal year ends in July.
Forecast for FY19:
Macquarie forecasts a full year FY19 dividend of 14.80 cents and EPS of 22.33 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 23.1, implying annual growth of N/A. Current consensus DPS estimate is 14.4, implying a prospective dividend yield of 5.0%. Current consensus EPS estimate suggests the PER is 12.5. |
Forecast for FY20:
Macquarie forecasts a full year FY20 dividend of 14.98 cents and EPS of 22.06 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 24.5, implying annual growth of 6.1%. Current consensus DPS estimate is 15.8, implying a prospective dividend yield of 5.5%. Current consensus EPS estimate suggests the PER is 11.8. |
This company reports in NZD. All estimates have been converted into AUD by FNArena at present FX values.
Market Sentiment: 0.5
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Morgan Stanley rates KMD as Equal-weight (3) -
FY18 earnings were in line with guidance and Morgan Stanley notes some moderation in same-store sales growth and margin in the second half. Momentum is expected to continue into the first half as the company cycles softer comparables and clearance activity. The three drivers of growth, in the broker's opinion, are online sales, Oboz and international sales.
Morgan Stanley is incrementally more positive but acknowledges that, in the apparel retailing world, things can change quickly, and wants to be more comfortable with in-store gains and international expansion. Equal-weight rating. Target is raised to $3.00 from $2.85. Industry view is In-Line.
Target price is $3.00 Current Price is $2.88 Difference: $0.12
If KMD meets the Morgan Stanley target it will return approximately 4% (excluding dividends, fees and charges).
Current consensus price target is $3.07, suggesting upside of 6.4% (ex-dividends)
The company's fiscal year ends in July.
Forecast for FY19:
Morgan Stanley forecasts a full year FY19 dividend of 15.53 cents and EPS of 24.81 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 23.1, implying annual growth of N/A. Current consensus DPS estimate is 14.4, implying a prospective dividend yield of 5.0%. Current consensus EPS estimate suggests the PER is 12.5. |
Forecast for FY20:
Morgan Stanley forecasts a full year FY20 dividend of 16.36 cents and EPS of 26.10 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 24.5, implying annual growth of 6.1%. Current consensus DPS estimate is 15.8, implying a prospective dividend yield of 5.5%. Current consensus EPS estimate suggests the PER is 11.8. |
This company reports in NZD. All estimates have been converted into AUD by FNArena at present FX values.
Market Sentiment: 0.5
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
MMS MCMILLAN SHAKESPEARE LIMITED
Vehicle Leasing & Salary Packaging
More Research Tools In Stock Analysis - click HERE
Overnight Price: $17.18
Ord Minnett rates MMS as Initiation of coverage with Buy (1) -
Ord Minnett is attracted to the McMillan Shakespeare business because of its leading presence in salary packaging and novated leasing and the customer engagement program, called Beyond 2020, presents a potential game changer for this division.
The broker suggests the opportunity for a significant increase in novated lease sales conversion is too good to miss and, if successful, would drive a significant increase in revenue and margin. Ord Minnett initiates coverage with a Buy rating and $20.50 target.
Target price is $20.50 Current Price is $17.18 Difference: $3.32
If MMS meets the Ord Minnett target it will return approximately 19% (excluding dividends, fees and charges).
Current consensus price target is $18.29, suggesting upside of 6.4% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY19:
Ord Minnett forecasts a full year FY19 dividend of 76.00 cents and EPS of 114.30 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 120.1, implying annual growth of 97.2%. Current consensus DPS estimate is 77.6, implying a prospective dividend yield of 4.5%. Current consensus EPS estimate suggests the PER is 14.3. |
Forecast for FY20:
Ord Minnett forecasts a full year FY20 dividend of 84.00 cents and EPS of 127.60 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 128.9, implying annual growth of 7.3%. Current consensus DPS estimate is 82.5, implying a prospective dividend yield of 4.8%. Current consensus EPS estimate suggests the PER is 13.3. |
Market Sentiment: 0.4
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Overnight Price: $3.70
Morgans rates NHC as Hold (3) -
New Hope's results beat the broker's estimates by 3-4% and the dividend also exceeded expectation. Management highlighted the progression of Lenton towards development and a reaffirmed focus on Acland, but also rising cost pressures.
Despite this, the broker calculates the company can maintain a 4% dividend yield and incremental growth at Lenton and still rapidly pay down the debt drawn to fund Bengalla. Target rises to $3.36 from $3.20 but Hold retained on full valuation.
Target price is $3.36 Current Price is $3.70 Difference: minus $0.34 (current price is over target).
If NHC meets the Morgans target it will return approximately minus 9% (excluding dividends, fees and charges - negative figures indicate an expected loss).
Current consensus price target is $3.14, suggesting downside of -15.2% (ex-dividends)
The company's fiscal year ends in July.
Forecast for FY19:
Morgans forecasts a full year FY19 dividend of 20.00 cents and EPS of 44.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 39.6, implying annual growth of 120.0%. Current consensus DPS estimate is 16.2, implying a prospective dividend yield of 4.4%. Current consensus EPS estimate suggests the PER is 9.3. |
Forecast for FY20:
Morgans forecasts a full year FY20 dividend of 15.00 cents and EPS of 30.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 30.0, implying annual growth of -24.2%. Current consensus DPS estimate is 15.0, implying a prospective dividend yield of 4.1%. Current consensus EPS estimate suggests the PER is 12.3. |
Market Sentiment: 0.3
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Overnight Price: $16.64
Morgan Stanley rates ORI as Overweight (1) -
Morgan Stanley believes the full impact of the company's manufacturing issues is yet to be fully reflected in the shares. Nevertheless, Orica remains positioned to benefit from the cyclical environment.
The broker suggests, thus far, there is little evidence that the Burrup plant will contribute meaningful volumes in FY19. Morgan Stanley lowers FY19-20 estimates for earnings per share by -6-8%.
The broker continues to believe FY18 will represent the trough in earnings and retains an Overweight rating. Target is reduced to $18.90 from $20.10. Industry view is Cautious.
Target price is $18.90 Current Price is $16.64 Difference: $2.26
If ORI meets the Morgan Stanley target it will return approximately 14% (excluding dividends, fees and charges).
Current consensus price target is $17.98, suggesting upside of 8.0% (ex-dividends)
The company's fiscal year ends in September.
Forecast for FY18:
Morgan Stanley forecasts a full year FY18 dividend of 48.00 cents and EPS of 82.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 69.4, implying annual growth of -32.4%. Current consensus DPS estimate is 48.0, implying a prospective dividend yield of 2.9%. Current consensus EPS estimate suggests the PER is 24.0. |
Forecast for FY19:
Morgan Stanley forecasts a full year FY19 dividend of 59.00 cents and EPS of 98.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 101.2, implying annual growth of 45.8%. Current consensus DPS estimate is 56.6, implying a prospective dividend yield of 3.4%. Current consensus EPS estimate suggests the PER is 16.4. |
Market Sentiment: 0.0
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Overnight Price: $2.98
Macquarie rates REG as Underperform (5) -
The Australian government has announced a royal commission into the aged care industry. Macquarie notes uncertainty exists regarding the potential fall-out from the inquiry, as well as negative media coverage on listed aged care operators.
Given the company's balance sheet and a mature portfolio that is already facing pressure, the broker retains an Underperform rating. Target is reduced to $2.57 from $3.43.
Target price is $2.57 Current Price is $2.98 Difference: minus $0.41 (current price is over target).
If REG meets the Macquarie target it will return approximately minus 14% (excluding dividends, fees and charges - negative figures indicate an expected loss).
Current consensus price target is $3.69, suggesting upside of 23.8% (ex-dividends)
The company's fiscal year ends in June.
Forecast for FY19:
Macquarie forecasts a full year FY19 dividend of 16.50 cents and EPS of 16.50 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 16.9, implying annual growth of -5.7%. Current consensus DPS estimate is 16.9, implying a prospective dividend yield of 5.7%. Current consensus EPS estimate suggests the PER is 17.6. |
Forecast for FY20:
Macquarie forecasts a full year FY20 dividend of 18.50 cents and EPS of 18.50 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 19.4, implying annual growth of 14.8%. Current consensus DPS estimate is 19.6, implying a prospective dividend yield of 6.6%. Current consensus EPS estimate suggests the PER is 15.4. |
Market Sentiment: 0.3
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Macquarie rates SCG as Neutral (3) -
Macquarie has been surprised by the extent of hoarded-up tenancies at the company's Chatswood and Sydney CBD assets. The broker notes retail leasing conditions remain challenged and the company's balance sheet is limited.
The stock is offering an improved dividend yield after de-rating, but soft retail fundamentals and limited capacity to step up the buyback in the absence of further asset sales causes the broker to maintain a Neutral rating. Target reduced to $4.34 from $4.45.
Target price is $4.34 Current Price is $4.14 Difference: $0.2
If SCG meets the Macquarie target it will return approximately 5% (excluding dividends, fees and charges).
Current consensus price target is $4.44, suggesting upside of 7.3% (ex-dividends)
The company's fiscal year ends in December.
Forecast for FY18:
Macquarie forecasts a full year FY18 dividend of 22.20 cents and EPS of 23.80 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 27.6, implying annual growth of 1050.0%. Current consensus DPS estimate is 22.1, implying a prospective dividend yield of 5.3%. Current consensus EPS estimate suggests the PER is 15.0. |
Forecast for FY19:
Macquarie forecasts a full year FY19 dividend of 22.40 cents and EPS of 25.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 25.5, implying annual growth of -7.6%. Current consensus DPS estimate is 22.8, implying a prospective dividend yield of 5.5%. Current consensus EPS estimate suggests the PER is 16.2. |
Market Sentiment: 0.1
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Overnight Price: $8.23
Citi rates TPM as Sell (5) -
FY18 net profit beat Citi's estimates and the main surprise was lower capital expenditure. The broker forecasts a further three years of earnings decline from the company's consumer division, with scope to grow from FY21 once NBN is complete and legacy voice and iiNet revenues are out of the system.
Prior to this, earnings growth will be required from mobile and cost synergies from the merger with Vodafone Australia. Sell rating maintained and target raised to $6.75 from $5.20.
Target price is $6.75 Current Price is $8.23 Difference: minus $1.48 (current price is over target).
If TPM meets the Citi target it will return approximately minus 18% (excluding dividends, fees and charges - negative figures indicate an expected loss).
Current consensus price target is $7.07, suggesting downside of -14.1% (ex-dividends)
The company's fiscal year ends in July.
Forecast for FY19:
Citi forecasts a full year FY19 dividend of 45.00 cents and EPS of 38.20 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 36.7, implying annual growth of -14.3%. Current consensus DPS estimate is 12.6, implying a prospective dividend yield of 1.5%. Current consensus EPS estimate suggests the PER is 22.4. |
Forecast for FY20:
Citi forecasts a full year FY20 EPS of 22.30 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 22.4, implying annual growth of -39.0%. Current consensus DPS estimate is 3.7, implying a prospective dividend yield of 0.4%. Current consensus EPS estimate suggests the PER is 36.7. |
Market Sentiment: -0.3
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Macquarie rates TPM as No Rating (-1) -
FY18 operating earnings were marginally ahead of recent guidance. Macquarie finds next year's guidance of $800-820m in earnings positive, given the company is expected to absorb -$65m in headwinds from the NBN roll-out and the loss of iiNet legacy fixed lines, as well as a -$10m negative impact from accounting changes.
Macquarie is unable to provide a valuation or rating at present because of research restrictions.
Current Price is $8.23. Target price not assessed.
Current consensus price target is $7.07, suggesting downside of -14.1% (ex-dividends)
The company's fiscal year ends in July.
Forecast for FY19:
Macquarie forecasts a full year FY19 dividend of 4.00 cents and EPS of 36.80 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 36.7, implying annual growth of -14.3%. Current consensus DPS estimate is 12.6, implying a prospective dividend yield of 1.5%. Current consensus EPS estimate suggests the PER is 22.4. |
Forecast for FY20:
Macquarie forecasts a full year FY20 dividend of 4.00 cents and EPS of 18.60 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 22.4, implying annual growth of -39.0%. Current consensus DPS estimate is 3.7, implying a prospective dividend yield of 0.4%. Current consensus EPS estimate suggests the PER is 36.7. |
Market Sentiment: -0.3
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Morgan Stanley rates TPM as Overweight (1) -
FY18 results were in line with guidance and expectations. Morgan Stanley notes there were no further comments on the merger with Vodafone Australia. Revenue was up 1% and operating earnings (EBITDA) were up 1%.
The company has guided to FY19 operating earnings of $800-820m (ex mobile) and this is in line with Morgan Stanley's estimates. Overweight rating and In-Line industry view. Target is $6.70.
Target price is $6.70 Current Price is $8.23 Difference: minus $1.53 (current price is over target).
If TPM meets the Morgan Stanley target it will return approximately minus 19% (excluding dividends, fees and charges - negative figures indicate an expected loss).
Current consensus price target is $7.07, suggesting downside of -14.1% (ex-dividends)
The company's fiscal year ends in July.
Forecast for FY19:
Morgan Stanley forecasts a full year FY19 EPS of 34.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 36.7, implying annual growth of -14.3%. Current consensus DPS estimate is 12.6, implying a prospective dividend yield of 1.5%. Current consensus EPS estimate suggests the PER is 22.4. |
Forecast for FY20:
Morgan Stanley forecasts a full year FY20 EPS of 25.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 22.4, implying annual growth of -39.0%. Current consensus DPS estimate is 3.7, implying a prospective dividend yield of 0.4%. Current consensus EPS estimate suggests the PER is 36.7. |
Market Sentiment: -0.3
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Morgans rates TPM as Add (1) -
TPG's result was in line with pre-released numbers, with earnings coming in slightly ahead of guidance. The main focus nonetheless is on the Vodafone merger, and on that subject there was no new news, other than an expectation the deal will be completed next year, pending approval.
The broker retains Add and a $10.70 target. The rating was lifted to Add on the announced merger given the significant synergies the broker sees being generated over time.
Target price is $10.70 Current Price is $8.23 Difference: $2.47
If TPM meets the Morgans target it will return approximately 30% (excluding dividends, fees and charges).
Current consensus price target is $7.07, suggesting downside of -14.1% (ex-dividends)
The company's fiscal year ends in July.
Forecast for FY19:
Morgans forecasts a full year FY19 dividend of 4.00 cents and EPS of 38.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 36.7, implying annual growth of -14.3%. Current consensus DPS estimate is 12.6, implying a prospective dividend yield of 1.5%. Current consensus EPS estimate suggests the PER is 22.4. |
Forecast for FY20:
Morgans forecasts a full year FY20 dividend of 4.00 cents and EPS of 23.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 22.4, implying annual growth of -39.0%. Current consensus DPS estimate is 3.7, implying a prospective dividend yield of 0.4%. Current consensus EPS estimate suggests the PER is 36.7. |
Market Sentiment: -0.3
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Ord Minnett rates TPM as Lighten (4) -
The outlook is now all about the proposed tie-in with Vodafone, but the analysts do not like the share price valuation, believed to be priced with a "Teoh Premium" included. The suggestion here is, with the process taking up 4-5 months, there will be a cheaper entry point.
The analysts also predict shareholders are likely to see a 57c special dividend coming their way. Lighten rating retained. Price target moves to $7.90 from $7.
This stock is not covered in-house by Ord Minnett. Instead, the broker whitelabels research by JP Morgan.
Target price is $7.90 Current Price is $8.23 Difference: minus $0.33 (current price is over target).
If TPM meets the Ord Minnett target it will return approximately minus 4% (excluding dividends, fees and charges - negative figures indicate an expected loss).
Current consensus price target is $7.07, suggesting downside of -14.1% (ex-dividends)
The company's fiscal year ends in July.
Forecast for FY19:
Ord Minnett forecasts a full year FY19 dividend of 4.00 cents and EPS of 35.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 36.7, implying annual growth of -14.3%. Current consensus DPS estimate is 12.6, implying a prospective dividend yield of 1.5%. Current consensus EPS estimate suggests the PER is 22.4. |
Forecast for FY20:
Current consensus EPS estimate is 22.4, implying annual growth of -39.0%. Current consensus DPS estimate is 3.7, implying a prospective dividend yield of 0.4%. Current consensus EPS estimate suggests the PER is 36.7. |
Market Sentiment: -0.3
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
UBS rates TPM as Sell (5) -
FY18 operating earnings were in line with expectations, given the company provided guidance less than three weeks ago. FY19 guidance of $800-820m is slightly conservative to UBS, once factoring in NBN headwinds and the reversal of promotional pricing benefits that were received in FY18.
The broker believes the proposed merger with Vodafone Australia makes sense, given the businesses are highly complementary from a customer perspective, asset mix and opportunity for cost synergies.
On balance, UBS assumes the deal will be approved but there are potential risks with the ACCC if it defines the relevant market as "converged" fixed and mobile telecommunications rather than more narrowly as mobile. Sell rating maintained. Target is reduced to $7.00 from $7.50.
Target price is $7.00 Current Price is $8.23 Difference: minus $1.23 (current price is over target).
If TPM meets the UBS target it will return approximately minus 15% (excluding dividends, fees and charges - negative figures indicate an expected loss).
Current consensus price target is $7.07, suggesting downside of -14.1% (ex-dividends)
The company's fiscal year ends in July.
Forecast for FY19:
UBS forecasts a full year FY19 dividend of 6.00 cents and EPS of 38.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 36.7, implying annual growth of -14.3%. Current consensus DPS estimate is 12.6, implying a prospective dividend yield of 1.5%. Current consensus EPS estimate suggests the PER is 22.4. |
Forecast for FY20:
UBS forecasts a full year FY20 dividend of 3.00 cents and EPS of 23.00 cents. How do these forecasts compare to market consensus projections? Current consensus EPS estimate is 22.4, implying annual growth of -39.0%. Current consensus DPS estimate is 3.7, implying a prospective dividend yield of 0.4%. Current consensus EPS estimate suggests the PER is 36.7. |
Market Sentiment: -0.3
All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources
Today's Price Target Changes
Company | Broker | New Target | Prev Target | Change | |
EHE | ESTIA HEALTH | Macquarie | 2.70 | 3.60 | -25.00% |
JHC | JAPARA HEALTHCARE | Macquarie | 1.33 | 1.77 | -24.86% |
KMD | KATHMANDU | Macquarie | 3.13 | 2.98 | 5.03% |
Morgan Stanley | 3.00 | 2.85 | 5.26% | ||
NHC | NEW HOPE CORP | Morgans | 3.36 | 3.20 | 5.00% |
ORI | ORICA | Morgan Stanley | 18.90 | 20.10 | -5.97% |
REG | REGIS HEALTHCARE | Macquarie | 2.57 | 3.43 | -25.07% |
SCG | SCENTRE GROUP | Macquarie | 4.34 | 4.45 | -2.47% |
TPM | TPG TELECOM | Citi | 6.75 | 5.20 | 29.81% |
Morgans | 10.70 | 10.40 | 2.88% | ||
Ord Minnett | 7.90 | 7.00 | 12.86% | ||
UBS | 7.00 | 7.50 | -6.67% |
Summaries
AFG | AUSTRALIAN FINANCE | Add - Morgans | Overnight Price $1.58 |
BRG | BREVILLE GROUP | Buy - Ord Minnett | Overnight Price $13.07 |
CGC | COSTA GROUP | Upgrade to Buy from Neutral - UBS | Overnight Price $6.81 |
CGF | CHALLENGER | Neutral - Credit Suisse | Overnight Price $10.94 |
CTX | CALTEX AUSTRALIA | Underweight - Morgan Stanley | Overnight Price $29.79 |
EHE | ESTIA HEALTH | Downgrade to Neutral from Outperform - Macquarie | Overnight Price $2.37 |
JHC | JAPARA HEALTHCARE | Downgrade to Underperform from Neutral - Macquarie | Overnight Price $1.35 |
KMD | KATHMANDU | Neutral - Credit Suisse | Overnight Price $2.88 |
Outperform - Macquarie | Overnight Price $2.88 | ||
Equal-weight - Morgan Stanley | Overnight Price $2.88 | ||
MMS | MCMILLAN SHAKESPEARE | Initiation of coverage with Buy - Ord Minnett | Overnight Price $17.18 |
NHC | NEW HOPE CORP | Hold - Morgans | Overnight Price $3.70 |
ORI | ORICA | Overweight - Morgan Stanley | Overnight Price $16.64 |
REG | REGIS HEALTHCARE | Underperform - Macquarie | Overnight Price $2.98 |
SCG | SCENTRE GROUP | Neutral - Macquarie | Overnight Price $4.14 |
TPM | TPG TELECOM | Sell - Citi | Overnight Price $8.23 |
No Rating - Macquarie | Overnight Price $8.23 | ||
Overweight - Morgan Stanley | Overnight Price $8.23 | ||
Add - Morgans | Overnight Price $8.23 | ||
Lighten - Ord Minnett | Overnight Price $8.23 | ||
Sell - UBS | Overnight Price $8.23 |
RATING SUMMARY
Rating | No. Of Recommendations |
1. Buy | 8 |
3. Hold | 6 |
4. Reduce | 1 |
5. Sell | 5 |
Wednesday 19 September 2018
Access Broker Call Report Archives here
Disclaimer:
The content of this information does in no way reflect the opinions of
FNArena, or of its journalists. In fact we don't have any opinion about
the stock market, its value, future direction or individual shares. FNArena solely reports about what the main experts in the market note, believe
and comment on. By doing so we believe we provide intelligent investors
with a valuable tool that helps them in making up their own minds, reading
market trends and getting a feel for what is happening beneath the surface.
This document is provided for informational purposes only. It does not
constitute an offer to sell or a solicitation to buy any security or other
financial instrument. FNArena employs very experienced journalists who
base their work on information believed to be reliable and accurate, though
no guarantee is given that the daily report is accurate or complete. Investors
should contact their personal adviser before making any investment decision.
Latest News
1 |
Monthly Listed Investment Trust Report – Oct 202412:00 PM - Australia |
2 |
The Case For Charter Hall11:30 AM - Australia |
3 |
Australian Listed Real Estate Tables – 07-10-202411:00 AM - Weekly Reports |
4 |
Australian Banks: When The End Of The Trend?10:38 AM - Feature Stories |
5 |
Weekly Ratings, Targets, Forecast Changes – 04-10-2410:00 AM - Weekly Reports |